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Background
Malaria during pregnancy is the cause of 1500 neonatal
deaths a day. Moreover, 40% of all low weight births are
caused by pregnancy associated malaria. Researchers at
Copenhagen University have identified the VAR2CSA
protein as a potential protective recombinant placental
malaria vaccine. ExpreS2ion Biotechnologies is responsi-
ble establishment of cell lines expressing VAR2CSA var-
iants and for developing the protein production process
based on VAR2CSA.
The ExpreS2 System is a one-for-all protein expression
system based on Drosophila S2 cells that is excellent in
all phases of Drug Discovery, R&D and manufacturing
due to high-level transient transfections, easy establish-
ment of stable polyclonal pools that provides continuous
high protein expression levels without selection pres-
sure, and simple cloning procedure. It is a novel, non-
viral, insect-cell based expression technology applied to
the development of a critically needed vaccine. The
VAR2CSA protein, which the vaccine is based on, is
hard to express and comparison studies between insect,
bacteria and yeast have shown that an insect cell system
is the only one leading to a clinically useful immune
response. Process optimization is also critically impor-
tant, as the cost of manufacture must be as low as possi-
ble to allow the vaccine to be used in the countries
where it is most needed.
Aim
The choice and cost of a manufacturing platform is one
of the most important strategic decisions in recombi-
nant subunit vaccine development. Furthermore, the
geographic distribution of malaria and the philanthropic
funding sources involved requires production to be as
cost-effective as possible. Single-use provides manufac-
turing flexibility and economic advantages, both highly
desirable in this type of process. We therefore aim to
develop cost-effective Drosophila S2 based Placental and
Blood-stage malaria vaccine production processes com-
bining the ExpreS2 constitutive insect cell expression
system with single-use bioreactor technology.
Materials and methods
Thirty-four truncation variants of the VAR2CSA placental
malaria vaccine antigen and full-length PfRh5 were cloned
into pExpreS2 vectors and transfected into Drosophila S2
insect cells. Stable cell lines were established in three
weeks in T-flask culture, which were then inoculated at
8E6 cells/ml in shake flasks, or batch or fed-batch produc-
tion in DasGip Bioreactors and harvested after 3 and 7
days respectively. The cultures were harvested by centrifu-
gation and filtration, where after the proteins were purified
using Ni++ affinity columns and gel filtration. Bioreactor
optimisation were performed in 1L DasGip mini-bioreac-
tors, 2L Braun glass bioreactor, and the single-use CellRea-
dy3L bioreactor. Alternating Tangential Flow (ATF)
technology from Refine was also employed for perfusion
production tests. The bioreactor conditions were 25°C,
pH6.5, Dissolved Oxygen 20%, 110 rpm stirrer speed using
a Marine impeller. The perfusion rate was set to 0.5 to 3
Reactor Volumes (RV) per day, but was increased signifi-
cantly faster for the CellReady 3L perfusion run compared
to the Braun runs, with 3 RV per day reached by day 6 vs.
day 9 for the Braun runs.
Results
Thirty-four protein variants of VAR2CSA were screened
for expression level. Further process optimization was
performed on the lead candidate in glass bioreactors,
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and >30% yield increase was achieved using a fed-batch
approach (results not shown). The expression of Rh5
was compared in batch, fed-batch and perfusion using
both CellReady3L and glass bioreactors. There was no
significant difference between growth in the DasGip
bioreactor and the disposable CellReady bioreactor.
Comparable yields were obtained in both systems
whether running in batch, fed-batch, or perfusion mode
(e.g. Perfusion day 6: 190 vs. 210 mg/L, results not
shown). Furthermore, 350E6 cells/ml were achieved in
concentrated perfusion mode using the ATF and Cell-
Ready3L. Concentrated perfusion lead to final Rh5 yields
of 210 mg/L and 500 mg/L after 6 or 9 days production
runs (see Figure 1).
Conclusions
The ExpreS2 platform has demonstrated its robustness of
expression ability, by expression of two complex malaria
antigens; and in breadth of hardware adaptability, as it was
shown to perform comparably in the single use CellReady3L
and glass bioreactors. Furthermore, extremely high cell
counts and yields of Rh5 were achieved in Fed-batch and
perfusion modes. The results demonstrate how the ExpreS2
expression system in conjunction with single-use technol-
ogy can be used to produce cost-effective malaria vaccines.
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Figure 1 Expression yields obtained for Rh5 in batch, fed-
batch and ATF-perfusion modes. Using perfusion could
significantly increase yields.
de Jongh et al. BMC Proceedings 2013, 7(Suppl 6):P20
http://www.biomedcentral.com/1753-6561/7/S6/P20
Page 2 of 2
